Abstract
BackgroundRecurrent and/or metastatic (R/M) disease develops in approximately 65% of patients with squamous cell carcinoma of the head and neck (SCCHN) and is associated with a poor prognosis. Immune checkpoint...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have